New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For APOL;EA;FLEX;GMCR;LRCX;MRVL;NFLX;RIMM;VRSN;WCRX From The Last 14 Days
Check below for free stories on APOL;EA;FLEX;GMCR;LRCX;MRVL;NFLX;RIMM;VRSN;WCRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | all recent news | >>
April 22, 2014
17:43 EDTNFLXNetflix expanding to France by year-end, Bloomberg says
Subscribe for More Information
16:33 EDTNFLXOn The Fly: Closing Wrap
Subscribe for More Information
14:28 EDTGMCRSunEdison, Conn's rally after Greenlight discloses new stakes
Subscribe for More Information
13:47 EDTMRVLMarvell firing 200 employees in Israel, Globes says
Subscribe for More Information
12:39 EDTNFLXOn The Fly: Midday Wrap
Stocks on Wall Street were higher at midday amid a number of big deals and a much talked about proposed deal in the pharmaceutical industry, as well as another wave of earnings reports. The market opened quietly but on the positive side of the ledger as investors pored over the multitude of quarterly reports issued after the close last night and earlier today. Near noon the market stood near its session highs and is pointing toward its sixth consecutive positive close. ECONOMIC EVENTS: In the U.S., existing home sales slipped 0.2% to a 4.59M rate in March, versus expectation for them to have fallen 1% to a 4.56M rate. The Richmond Fed manufacturing survey for April had a reading of 7, beating the consensus forecast for a reading of 2. COMPANY NEWS: Valeant Pharmaceuticals (VRX) teamed with Bill Ackman's hedge fund Pershing Square to make a hostile takeover offer for Allergan (AGN), sending shares of both companies higher. Allergan confirmed it received the offer of $48.30 in cash and 0.83 shares of Valeant stock for each of its own shares, which it said it will evaluate with the help of its advisers. Analysts' opinion on the fallout varied, with one firm suggesting Allergan could pursue its own takeover of Shire (SHPG) or Jazz Pharmaceuticals (JAZZ) as a defense, and another saying a rival big pharma company, such as Johnson & Johnson (JNJ) or Merck (MRK), could launch a competing bid for Allergan. Shares of Allergan led all gainers on the S&P 500, rising 16%, while Valeant shares gained more than 6%... A number of other big drug makers made news with a string of deals, as Novartis (NVS) and GlaxoSmithKline (GSK) both reshaped their companies via a trio of agreements. Novartis will acquire GSK's oncology products for a $14.5B payment and up to $1.5B contingent future payments, Novartis will sells its Vaccines business, excluding flu, to GSK for $7.1B plus royalties, and the two agreed to tie-up their consumer healthcare businesses through a joint venture. In a separate transaction, Novartis agreed to divest its Animal Health Division to Eli Lilly (LLY) for about $5.4B. MAJOR MOVERS: Among the notable gainers following their earnings reports were streaming video service Netflix (NFLX), which advanced almost 6%, and motorcycle maker Harley-Davidson (HOG), which rose 8%. Companies that slid following their earnings reports included printer maker Lexmark (LXK), which fell over 11%, and Pentair (PNR), which dropped almost 6%. INDEXES: Near midday, the Dow was up 106.77, or 0.65%, to 16,556.02, the Nasdaq was up 45.95, or 1.11%, to 4,167.50, and the S&P 500 was up 11.59, or 0.62%, to 1,883.48.
12:37 EDTNFLXNetflix rises after earnings beat, sooner than expected price hike
Subscribe for More Information
12:19 EDTLRCXLam Research management to meet with Pacific Crest
Subscribe for More Information
10:42 EDTNFLX Options with decreasing implied volatility: SRPT NFLX YOKU UVXY
Subscribe for More Information
10:00 EDTNFLXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:38 EDTNFLXActive equity options trading on open
Subscribe for More Information
09:16 EDTNFLXOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Netflix (NFLX), up 8%... Harley-Davidson (HOG), up 7%... PLX Technology (PLXT), up 8%... Illinois Tool (ITW), up 2.3%... Comcast (CMCSA), up 1%... McDonald's (MCD), up 0.6%. ALSO HIGHER: Allergan (AGN), up 17% after Valeant (VRX) confirms proposal to combine with the company for $48.30 and 0.83 shares of stock. Valeant is up 5% following its confirmation of the news that broke last night... GlaxoSmithKline (GSK), up 4.5% after agreeing to sell oncology products for $14.5B to Novartis (NVS) and buy Novartis' Vaccines business, currently excluding its flu business, for $7.1B plus royalties. Novartis shares trading in New York are also up 1% following the deals... Revance Therapeutics (RVNC), up 20% after announcing positive results from RT002 Phase 1/2 study... Facebook (FB), up 2% following upgrade at Credit Suisse. DOWN AFTER EARNINGS: Xerox (XRX), down 4%... Lexmark (LXK), down 4.8%. ALSO LOWER: Allison Transmission (ALSN), down 4% after filing to sell 25M shares for holders... FireEye (FEYE), down 2.9% after filing to sell 13.3M shares of common stock for holders... Bebe stores (BEBE), down 16% after reporting preliminary Q3 losses that were steeper than the consensus estimate.
08:14 EDTNFLXNetflix price target raised to $520 from $500 at Pacific Crest
Subscribe for More Information
07:50 EDTNFLXNetflix price target raised to $435 from $419 at Oppenheimer
Subscribe for More Information
07:34 EDTNFLXNetflix guidance, commentary positive, says Stifel
Subscribe for More Information
07:10 EDTNFLXNetflix blames AT&T for below-average streaming speeds, Bloomberg says
Subscribe for More Information
05:59 EDTNFLXNetflix price target raised to $434 from $412 at Piper Jaffray
Subscribe for More Information
05:45 EDTNFLXNetflix upgraded to Outperform from Market Perform at Raymond James
Subscribe for More Information
05:30 EDTNFLXNetflix upgraded to Buy from Hold at Cantor
Cantor Fitzgerald upgraded its rating on Netflix (NFLX) shares to Buy from Hold citing the company's stronger than expected Q1 results and better Q2 guidance. Cantor views the stock as more compelling given Netflix's international expansion and $1-$2 price hike later this quarter. The firm raised its price target for shares to $425 from $405.
April 21, 2014
19:45 EDTNFLXComcast responds to Netflix opposition to Time Warner Cable deal
Subscribe for More Information
19:02 EDTNFLXOn The Fly: After Hours Movers
NOTABLE: Allergan (AGN), up 20%, and Valeant Pharmaceuticals (VRX), up 9.1%, both advanced after The Wall Street Journal reported that activist investor Bill Ackman is teaming up with Valeant to make a bid for Allergan. Following the report, Ackman's Pershing Square filed a 13D with the SEC disclosing a 9.7% stake in Allergan and outlining an agreement with Valeant. The agreement, among other things, said that Valeant plans to make a bid for Allergan comprised of $15B of cash and a to-be-determined amount of Valeant stock. The filing also showed that Ackman began building a position in Allergan in late February, and at that time entered an agreement with Valeant forming a new, jointly-owned entity through which to acquire a position in Allergan. CNBC's David Faber reported that Valeant is expected to officially make a hostile bid for Allergan by tomorrow. UP AFTER EARNINGS: Netflix (NFLX) gained 6.3% after reporting profits that beat expectations on revenues that were in-line with expectations. The streaming internet video service also reported that U.S. subscribers grew by 2.25M in the first quarter, with its international subscriber base expanding by 1.75M for the period. DOWN AFTER EARNINGS: Rambus (RMBS) fell 7.5% after providing a second quarter revenue outlook that fell short of expectations, with the company adding that its revenue outlook, "includes expectations that the company will sign new customers for patent as well as solutions licensing." Rambus' first quarter results, however, came in better than expected, and the company also reaffirmed its fiscal 2014 revenue outlook.
<< 1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use